Gossamer Bio (GOSS) Cash & Equivalents (2018 - 2026)

Gossamer Bio's Cash & Equivalents history runs 9 years deep, the most recent figure standing at $41.0 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 41.37% year-over-year to $41.0 million; the TTM figure through Mar 2026 stood at $41.0 million (up 41.37% YoY), while the FY2025 annual figure was $37.7 million, up 49.14% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $41.0 million, up from $37.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $138.9 million in Q1 2022, with the low at $4.2 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $37.0 million (2023), against an average of $48.7 million.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents soared 1019.73% in 2022, then tumbled 96.98% in 2023.
• Gossamer Bio's Cash & Equivalents stood at $112.0 million in 2022, then sank by 71.32% to $32.1 million in 2023, then decreased by 21.21% to $25.3 million in 2024, then soared by 49.14% to $37.7 million in 2025, then climbed by 8.74% to $41.0 million in 2026.
• Business Quant data shows GOSS's Cash & Equivalents at $41.0 million in Q1 2026, $37.7 million in Q4 2025, and $8.9 million in Q3 2025.